FDA tightens warnings for Astellas stress agents but generics a bigger threat?
This article was originally published in Scrip
Two cardiac stress test agents marketed in the US by Astellas Pharma are the subject of a new warning from the FDA over a "rare but serious risk of heart attack and death" in certain patients, prompted by recent reports of serious adverse events.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.